Clearmind Medicine Files International Patent For Ibogaine Combination Therapy

Clearmind Medicine Inc. CMND filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines.

What Happened: The therapy was developed in collaboration with SciSparc Ltd. SPRC. It combines the psychedelic compound Ibogaine with Palmitoylethanolamide (PEA), which is a member of the N-Acylethanolamines family. It aims to improve the safety and efficacy of Ibogaine-based treatments.

Ibogaine, derived from the African shrub Tabernanthe iboga, has already shown potential in addressing opioid, cocaine, and other substance use disorders.

See Also: GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates

Why It Matters: The patent signifies a significant advancement in treating mental health and substance use disorders.

Ibogaine has also garnered attention in clinical trials for its effectiveness in combating addiction. However, its use has not been without controversy. There are reports of adverse effects or fatalities related to the ingestion of iboga or Ibogaine.

Clearmind Medicine’s combination seeks to mitigate these risks while enhancing the therapeutic benefits of the treatment.

"The publication of this patent highlights Clearmind's commitment to leadership in the psychedelics space through building a diverse patent portfolio, featuring technologies with varying timelines to market,” Clearmind Medicine CEO Adi Zuloff-Shani said. “Most importantly, we aim to provide safe and effective solutions for mental health conditions that currently have unmet needs."

SciSparc specializes in treatments targeting central nervous system disorders. The company has been exploring cannabinoid-based therapeutics, which complement Clearmind’s work in psychedelic research.

SciSparc’s experience in clinical-stage pharmaceuticals provides critical expertise in advancing the therapy.

Together, Clearmind and SciSparc are working on expanding the scope of their research to address various mental health issues, particularly focusing on safe and effective solutions for addiction.

Clearmind Medicine’s intellectual property portfolio currently comprises of 19 patent families and 29 granted patents.

Now Read:

• Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials

Cover image made with AI